Skip to main content

Table 1 Study-, patient- and intervention characteristics

From: The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis

 

Study characteristics

Patient characteristics

Intervention characteristics

Countrya

Follow-up (months)

Study designb

Sample size at baselinec

No of patients who completed studyc

Mean age

Sex (% male)

FEV1% predicted

% with a history of ≥ 1 exacerbation in year prior to study

Smoking status (% smokers)

Interventions categories according to CCM components*

Professions involved in delivering of the DM program**

I

C

I

C

I

C

I

C

I

C

I

C

I

C

SMS

DEC

DSD

CIS

Total

RS

RN

GP

PHY

DIE

PHA

SW

Total

[36]

NL

12

Pre-post

317

NA

222

NA

61

NA

56

NA

56

NA

NS

NS

40

NA

âś“

âś“

âś“

âś“

4

âś“

âś“

âś“

    

3

[31]

NL

24

RCT

102

97

77

81

66

67

71

71

49

51

1.2

1.0

33

24

âś“

âś“

âś“

 

3

âś“

âś“

 

âś“

âś“

  

4

[37]

FR

12

RCT

23

22

20

18

65

61

90

78

56

54

NS

NS

25

28

âś“

   

1

NS

NS

NS

NS

NS

NS

NS

NS

[39]

USA

12

Case-control

94

47

NA

NA

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

âś“

âś“

âś“

 

3

âś“

âś“

âś“

    

3

[28]

NOR

12

RCT

31

31

26

27

57

58

48

52

52

55

NS

NS

39

39

âś“

âś“

  

2

âś“

âś“

âś“

âś“

 

âś“

 

5

[38]

CAN

12

RCT

96

95

86

79

70

69

52

59

45

46

NS

NS

25

26

âś“

âś“

âś“

 

3

âś“

âś“

âś“

    

3

[29]

NL

12

RCT

127

121

122

114

65

65

85

84

56

58

1.4

1.3

28

26

âś“

   

1

âś“

  

âś“

   

2

[30]

UK

24

RCT

61

61

55

49

70

70

49

49

43

49

100e

100

30

20

âś“

 

âś“

 

2

 

âś“

âś“

    

2

[34]

USA

12

RCT

372

371

336

323

69

71

98

98

36

38

100

100

22

23

âś“

âś“

âś“

 

3

âś“

âś“

 

âś“

   

3

[32]

NZ

12

Case-control

16

16

NA

NA

70

75

63

56

26

NSd

100

100

13

19

âś“

 

âś“

 

2

âś“

âś“

âś“

   

âś“

4

[33]

USA

12

Pre-post

524

NA

349

NA

64

NA

51

NA

NS

NA

NS

NA

NS

NA

âś“

âś“

âś“

 

3

âś“

âś“

âś“

    

3

Total (%)

100

64

73

9

 

90

90

70

40

10

10

10

 
  1. a NL Netherlands, FR France, USA United States of America, NOR Norway, CAN Canada, UK United Kingdom, NZ New Zealand, b RCT Randomized Control Trial, c I Intervention, C comparison, d FEV 1 Control group 0.72 ± 0.22L, e in the last 4 years; NS Not stated, NA Not applicable, *SMS Self-management support, DEC Decision support, DSD Delivery system design, CIS Clinical information system, **RS Respiratory/chest specialist, RN Respiratory nurse, GP General practitioner, PHY Physiotherapist, DIE Dietician, PHA Pharmacist, SW Social worker.